Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

In pharmacovigilance, effective search strings are key

Posted on February 9th, 2018 by

A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. Continue reading “In pharmacovigilance, effective search strings are key” »

Why a reliable FAERS searching capability is essential for pharma companies

Posted on October 27th, 2017 by

In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »

Big Data and Proactive Pharmacovigilance

Posted on September 20th, 2017 by

Traditionally thought of as a post-market process, pharmacovigilance is how pharmaceutical companies monitor and address any safety issues that arise once a drug becomes available commercially. However, some companies are now thinking ahead about these potential safety concerns with what is known as “proactive PV”. Continue reading “Big Data and Proactive Pharmacovigilance” »

The Challenges of Signal Detection in Spontaneous Reporting

Posted on September 13th, 2017 by

Pharmacovigilance is essential to pharmaceutical businesses. It facilitates the correct use of a drug, safeguarding the drug as a meaningful treatment option when the benefits it offers outweigh known risks, or measures can be taken to mitigate those risks. Continue reading “The Challenges of Signal Detection in Spontaneous Reporting” »

  1. 1
  2. 2
  3. 3
  4. 16